Pancreatic Cancer
Pancreatic cancer, specifically pancreatic adenocarcinoma, is a type of cancer that begins in the cells of the pancreas, often leading to symptoms like abdominal pain, weight loss, and jaundice.
Pancreatic Cancer: New Treatment Combination Study
We are studying a new treatment combining autogene cevumeran, atezolizumab, and mFOLFIRINOX for patients with resected pancreatic ductal adenocarcinoma. The goal is to see if this combination improves survival compared to standard mFOLFIRINOX alone.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently pregnant or breastfeeding?
- Have you had any treatment for pancreatic cancer, like chemotherapy or radiation, before this study?
- Do you have any serious medical conditions that your doctor has said would prevent you from safely participating in a study?
- Have you had any major complications after your pancreatic surgery?
- Is your carbohydrate antigen 19-9 (CA19-9) level known and was it measured within the last 14 days?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Az Maria Middelares Gent
Digestive Oncology
Gent, Belgium
UZ Leuven
Digestive Oncology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Oncology
Ledeberg, Belgium
Sponsor: Genentech Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.